Skip to content

REGEN BIOPHARMA, INC.: 10-Q filed 2023-07-25

What REGEN BIOPHARMA, INC. reported in its quarterly report filed 2023-07-25 (fiscal Q3 2023): 25 published measures, 78 facts as tagged in accession 0001607062-23-000371.

This filing

Form
10-Q (quarterly report)
Filed
2023-07-25
Fiscal period
fiscal Q3 2023
Accession
0001607062-23-000371 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All REGEN BIOPHARMA, INC. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2023-06-30285,196USD
At 2022-09-30559,002USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

PeriodValueUnitDays
At 2023-06-305,314,169USD
At 2022-09-308,595,061USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2023-06-30-5,028,973USD
At 2023-03-31-4,929,755USD
At 2022-12-31-4,884,827USD
At 2022-09-30-8,036,059USD
At 2022-06-30-8,349,684USD
At 2022-03-31-76,749,430USD
At 2021-12-31-9,755,969USD
At 2021-09-30-13,485,877USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2023-04-01 to 2023-06-30-99,218USD91
2022-10-01 to 2023-06-301,481,534USD273
2022-04-01 to 2022-06-3066,958,167USD91
2021-10-01 to 2022-06-302,521,557USD273

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

PeriodValueUnitDays
2022-10-01 to 2023-06-30-150,512USD273
2021-10-01 to 2022-06-30-521,634USD273

Revenue

Revenue under this specific accounting concept. A missing value is not zero; filers can use other revenue concepts.

PeriodValueUnitDays
2023-04-01 to 2023-06-3031,640USD91
2022-10-01 to 2023-06-3094,920USD273
2022-04-01 to 2022-06-3031,292USD91
2021-10-01 to 2022-06-3093,877USD273

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

PeriodValueUnitDays
2022-10-01 to 2023-06-30100,000USD273
2021-10-01 to 2022-06-30-94,535USD273

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

PeriodValueUnitDays
At 2023-06-30-19,423,836USD
At 2022-09-30-20,905,369USD

Basic weighted-average shares

Time-weighted shares used for basic earnings per share. This denominator differs from shares outstanding at a single reporting date.

PeriodValueUnitDays
2023-04-01 to 2023-06-303,381,366shares91
2022-10-01 to 2023-06-303,370,012shares273
2022-04-01 to 2022-06-303,189,187shares91
2021-10-01 to 2022-06-303,196,085shares273

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

PeriodValueUnitDays
2023-04-01 to 2023-06-30-85,155USD91
2022-10-01 to 2023-06-30-627,863USD273
2022-04-01 to 2022-06-30-58,910USD91
2021-10-01 to 2022-06-30-241,826USD273

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

PeriodValueUnitDays
At 2023-06-3062,616USD
At 2022-09-30336,422USD

Interest expense

Borrowing costs recognized as interest expense. This is distinct from cash interest paid and may not include every capitalized borrowing cost.

PeriodValueUnitDays
2023-04-01 to 2023-06-3014,063USD91
2022-10-01 to 2023-06-3043,507USD273
2022-04-01 to 2022-06-3030,399USD91
2021-10-01 to 2022-06-30107,970USD273

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

PeriodValueUnitDays
At 2023-06-305,314,169USD
At 2022-09-308,595,061USD

Current accounts payable

Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.

PeriodValueUnitDays
At 2023-06-3029,403USD
At 2022-09-3028,799USD

Net current accounts receivable

Current customer receivables after the allowance for credit loss. The balance is not cash collected or a guarantee of collection.

PeriodValueUnitDays
At 2023-06-3056,547USD
At 2022-09-30254,273USD

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

PeriodValueUnitDays
2023-04-01 to 2023-06-3045,001USD91
2022-10-01 to 2023-06-30176,960USD273
2022-04-01 to 2022-06-3031,061USD91
2021-10-01 to 2022-06-3093,869USD273

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

PeriodValueUnitDays
At 2023-06-303,381,366shares
At 2022-09-303,354,866shares

Cash including restricted cash

Cash, cash equivalents and restricted cash as reported in the cash flow reconciliation. Restricted amounts are not freely available, so this is not the same as unrestricted cash.

PeriodValueUnitDays
At 2023-06-30692USD
At 2022-09-3051,204USD
At 2022-06-30110,993USD
At 2021-09-30727,162USD

Additional paid-in capital

Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.

PeriodValueUnitDays
At 2023-06-3013,658,153USD
At 2022-09-3011,581,499USD

Total equity including noncontrolling interests

Equity including the portion attributable to noncontrolling interests. It is larger than or equal to parent stockholders equity and is not market capitalization.

PeriodValueUnitDays
At 2023-06-30-5,028,973USD
At 2022-09-30-8,036,059USD

Profit or loss including noncontrolling interests

Net income or loss including the portion attributable to noncontrolling interests. It can differ from the net income attributable to the parent that per-share figures use.

PeriodValueUnitDays
2023-04-01 to 2023-06-30-99,218USD91
2023-01-01 to 2023-03-31-54,978USD90
2022-10-01 to 2022-12-311,635,730USD92
2022-04-01 to 2022-06-3066,958,167USD91
2022-01-01 to 2022-03-31-67,081,589USD90
2021-10-01 to 2021-12-312,644,980USD92

Net income available to common stockholders

Net income after preferred dividends and similar adjustments, the numerator for basic earnings per share. It can be lower than reported net income.

PeriodValueUnitDays
2023-04-01 to 2023-06-30-99,218USD91
2022-10-01 to 2023-06-301,303,750USD273
2022-04-01 to 2022-06-3060,931,931USD91
2021-10-01 to 2022-06-302,294,618USD273

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

PeriodValueUnitDays
2023-04-01 to 2023-06-309,262USD91
2022-10-01 to 2023-06-3036,660USD273
2022-04-01 to 2022-06-306,866USD91
2021-10-01 to 2022-06-3018,879USD273

Change in accounts receivable

The cash flow adjustment for the change in receivables during the period. A positive value under this concept means receivables grew and reduced operating cash flow.

PeriodValueUnitDays
2022-10-01 to 2023-06-30-197,725USD273
2021-10-01 to 2022-06-3082,275USD273

Change in accounts payable

The cash flow adjustment for the change in payables during the period. A positive value under this concept means payables grew and added to operating cash flow.

PeriodValueUnitDays
2022-10-01 to 2023-06-30604USD273
2021-10-01 to 2022-06-30-62,705USD273

Inspect the source

Entity
REGEN BIOPHARMA, INC. / CIK 0001589150
Captured
2026-09-20T09:23:48.532Z
SEC response SHA-256
0bbe246b6080c7701ba978807745a4ba9de62971ab4db32e8d3e2fa2c4f26a87

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001589150.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))